Hereditary angioedema (HAE) is a type of rare genetic disorder that is often characterized by recurring episodes of angioedema or severe swelling owing to dysfunction or deficiency of C1 inhibitor in the individuals’ blood. The recurrent episodes of the condition are caused due to triggers such as anxiety, dental procedures, surgery, medications and illnesses. The swelling is primarily observed in face, limbs, airway and intestinal tract of the individuals with hereditary angioedema.
The major factor contributing to the growth of the hereditary angioedema therapeutics market is the considerable patient population observed across the globe. Although the reported prevalence of the condition ranges between 1-9 individuals per 100,000 population according to data provided by organizations such as National Organization for Rare Disorders (NORD), Orphanet, etc. the actual number of people suffering from the disorder remains significantly higher owing to misdiagnosis and under-reporting. According to a 2016 study published in Annals of Allergy, Asthma & Immunology more than 50% of the patients covered in the study were misdiagnosed for the condition leading to inadequate treatment along with unnecessary procedures. Most of the misdiagnoses were related to allergic angioedema, appendicitis, other non-allergic angioedema, etc. The high proportion of patients being misdiagnosed for the disorder has led to significant unmet clinical needs for the patients, which is expected to help in driving the demand for appropriate treatment therapies used in the management of the disorder.
Initiatives aimed at boosting the awareness levels among the population for hereditary angioedema is also likely to help in improving the diagnosis levels for the condition and in turn driving the uptake of medications such as C1 Esterase Inhibitor among others used to manage the disorder. Every year 16th May is celebrated as HAE awareness day by patient organizations led by HAE International (HAEi), which is a global umbrella organization dedicated for the world’s HAE patient groups. HAEi has introduced support family testing tools on its website, aimed at improving awareness levels for C1 inhibitor deficiencies that is expected to help in facilitating accurate diagnosis and medical care for the condition.
Based on drug class, the global hereditary angioedema therapeutics market is segmented into B2 bradykinin receptor antagonist, kallikrein inhibitor, C1 esterase inhibitor, and others. C1 esterase inhibitor drug class is expected to account for significant market share owing to spate of regulatory approvals for expanded label applications. For instance, In June 2018, the U.S. Food and Drug Administration (FDA) granted regulatory approval for label expansion for Shire plc’s CINRYZE. The approval paves the way for use of the drug in the management of HAE in pediatric patients aged 6 years and above in the U.S.
In terms of treatment type, the global hereditary angioedema therapeutics market is segmented into prophylaxis and on-demand treatment. Higher number of options for on-demand treatment such as C1 esterase inhibitor, kallikrein inhibitor, B2 bradykinin receptor antagonist, etc. as compared to prophylactic treatment, which has a relatively limited products, has aided in dominance of the former segment.
On the basis of route of administration, the global hereditary angioedema therapeutics market is divided into intravenous, subcutaneous and oral segments. Promising pipeline of intravenous and subcutaneous hereditary angioedema products is expected to facilitate robust growth of these two segments during the forecast period.
According to the region, the global hereditary angioedema therapeutics market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East Asia. North America accounted for the leading share of the market in 2017 on account of commercial availability of drugs used in the management of hereditary angioedema, new product launches and development of novel approaches used for preventing hereditary angioedema attacks.
Prominent industry participants in the global hereditary angioedema therapeutics market include BioCryst Pharmaceuticals, Inc, CSL Limited, Ionis Pharmaceuticals, Inc., Pharming Group N.V., Shire Plc, among others.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."